A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

OBJECTIVE: To compare the efficacy, safety, and anti-inflammatory effects of cenicriviroc (CVC), an oral, once-daily C-C chemokine receptor types 5 and 2 antagonist, with those of efavirenz (EFV) in treatment-naive, HIV-1-infected adults. DESIGN: A 48-week, randomized, double-blind, double-dummy pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Melanie, Saag, Michael, DeJesus, Edwin, Gathe, Joseph, Lalezari, Jay, Landay, Alan L., Cade, Jerry, Enejosa, Jeffrey, Lefebvre, Eric, Feinberg, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794136/
https://www.ncbi.nlm.nih.gov/pubmed/26636929
http://dx.doi.org/10.1097/QAD.0000000000000988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794136/
https://www.ncbi.nlm.nih.gov/pubmed/26636929
http://dx.doi.org/10.1097/QAD.0000000000000988

Ejemplares similares